News
NANOBIOTIX Files Registration Statement for Proposed Initial Public Offering in the United States
Regulatory News:
NANOBIOTIX (Paris:NANO) (Euronext: NANO – ISIN : FR0011341205 – the ‘‘Company’’), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer
Clovis Oncology to Present at the Piper Sandler 32nd Annual Healthcare Conference
Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that a pre-recorded fireside chat with President and Chief Executive Officer Patrick J. Mahaffy will be available next week for replay as part
Puma Biotechnology to Present Neratinib Data at the San Antonio Breast Cancer Symposium (SABCS)
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced the release of 10 abstracts that will be presented at the 2020 Virtual San Antonio Breast Cancer Symposium (SABCS)
Nanobiotix Announces Two New Phase II Trials Evaluating NBTXR3 in Combination with Anti-PD-1 for the Treatment of Head and Neck Cancer
Regulatory News:
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205 – the “Company”) (Paris:NANO), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today
EnWave Signs Equipment Purchase Agreement GEA Lyophil GmbH and advances Joint Pharmaceutical Technology Development
Vancouver, B.C., November 13, 2020
EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the “Company” - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/) announced
EnWave unterzeichnet Anlagenkaufvertrag mit GEA Lyophil GmbH und treibt gemeinsame Entwicklung der pharmazeutischen Technologie voran
Vancouver, B.C., 13. November 2020
Die EnWave Corporation (TSX-V:ENW | FSE:E4U) ("EnWave", oder das "Unternehmen" - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/) gab
IMV to Host a Key Opinion Leader Webcast on the Ovarian Cancer Treatment Landscape and Data Highlights from the Phase 2 Trial of a Novel T-Cell Therapy
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today announced that the
Aurinia Pharmaceuticals to Present at the 2020 Jefferies Virtual London Healthcare Conference
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the senior management team will participate in a fireside chat during the 2020 Jefferies
Navidea Biopharmaceuticals Announces Positive Results Encompassing Additional Patients From Its Ongoing Phase 2B Study in Rheumatoid Arthritis
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to
Navidea Biopharmaceuticals Reports Third Quarter and Year-to-Date 2020 Financial Results
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
EnWave unterzeichnet erste kommerzielle Lizenz zur Zahlung von Lizenzgebührenür die Verarbeitung von Cannabis in den Vereinigten Staaten
Vancouver, B.C., 12. November 2020
Die EnWave Corporation (TSX-V:ENW | FSE:E4U) ("EnWave", oder das "Unternehmen" - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/ ) gab
EnWave Signs First Commercial Royalty-Bearing License for Cannabis Processing in the United States
Vancouver, B.C., November 12 , 2020
EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the “Company” - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/) announced
IMV Inc. Announces Third Quarter 2020 Financial Results and Provides Clinical Update
IMV Inc. (the “Company” or “IMV”) (TSX: IMV; NASDAQ: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases
NANOBIOTIX Announces Positive New Pre-clinical Data Suggesting Radioenhancer NBTXR3 Could Have a Significant Impact in Immunotherapy
NANOBOTIX (Euronext: NANO - ISIN: FR0011341205 – the “Company”), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced positive new in vivo
Medigene AG: Medigene provides Q3 2020 update
Business news for the stock market
Planegg/Martinsried (12.11.2020) - Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development
Medigene AG: Medigene berichtet über Q3 2020
Unternehmensmitteilung für den Kapitalmarkt
Planegg/Martinsried (12.11.2020) - Die Medigene AG (Medigene, FWB: MDG1, Prime Standard), ein Immunonkologie-Unternehmen mit klinischen Projekten
Savara to Present at the Jefferies Virtual London Healthcare Conference
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Matthew Pauls, Chairman and Interim CEO, will be presenting at the Jefferies Virtual London Healthcare Conference on
Deciphera Presents Updated Preliminary Data from DCC-3014, its CSF1R Inhibitor Program, in Tenosynovial Giant Cell Tumor Patients at the Connective Tissue Oncology Society (CTOS) 2020 Virtual Annual Meeting
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), today announced the presentation of encouraging preliminary results from the ongoing Phase 1/2 study of DCC-3014, a highly selective, oral
Deciphera Presents Data from QINLOCK® (Ripretinib) Program at the Connective Tissue Oncology Society (CTOS) 2020 Virtual Annual Meeting
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), today announced data presentations from clinical studies of QINLOCK, the Company’s switch-control tyrosine kinase inhibitor approved in the U.S. for
Aurinia Reports Third Quarter 2020 Financial Results and Recent Operational Highlights
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”) today reported financial results for the third quarter ended September 30, 2020 and provided an update on recent
IMV Strengthens Leadership Team with Appointment of Andrew Hall as Chief Business Officer
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today announced the
Deciphera Pharmaceuticals, Inc. to Present at the Jefferies Virtual London Healthcare Conference
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), today announced that Steve Hoerter, President and Chief Executive Officer, will present at the Jefferies Virtual London Healthcare Conference on
NANOBIOTIX Announces Positive First Clinical Data Showing Conversion of Anti-PD-1 Non-Responders to Responders With Radioenhancer NBTXR3
Regulatory News:
NANOBIOTIX (Paris:NANO) (Euronext: NANO - ISIN: FR0011341205 – the “Company”), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today
IMV to Participate in Two Upcoming Investor Conferences
IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious
Aurinia Presents Integrated Time to Renal Response Data from the AURA-LV and AURORA Trials, along with Voclosporin Drug-Drug Interaction Data at ACR Convergence 2020
Aurinia Pharmaceuticals Inc. (Nasdaq: AUPH / TSX:AUP) (Aurinia or the Company), a late-stage clinical biopharmaceutical company, today announced data from an integrated analysis of the AURA-LV and